Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H107e/CAF®10b TB Vaccine in Adults
NCT06050356Phase 1Active, not recruiting
- Sponsor
- Statens Serum Institut
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H107e + CAF10b in Tuberculosis (TB) (9 arms), sponsored by Statens Serum Institut. Primary endpoints: Percentage of participants with solicited injection site reactions at Day 36, Percentage of participants with solicited systemic reactions at Day 36 and 6 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
H107e + CAF10b
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06050356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050356.